Thursday, February 22, 2018
 
 
Company News: Page (1) of 1 - 02/09/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Greenberg Traurig Hosts Boston Healthcare Drinks and Dr. Preston Estep for Discussion on Genomics
 
(February 09, 2018)
Greenberg Traurig Hosts Boston Healthcare Drinks and Dr. Preston Estep for Discussion on Genomics

On Monday, Feb. 12, Greenberg Traurig, LLP's Boston office will sponsor and host the Boston Healthcare Drinks' event, featuring Dr. Preston Estep, Director of Gerontology and Director of Collections for the Personal Genome Project at Harvard University. Dr. Estep will share his insights on how genomics is changing human health and longevity.

Prior to Dr. Estep's talk, Dr. Fang Xie and Wayne H. Elowe, leaders of the firm's Biotechnology and Pharmaceutical Industry Group of the Global Life Sciences & Medical Technology Group, will discuss key IP and corporate issues that pharma and medical device companies should be aware of when doing business in China.

In 2016, Greenberg Traurig sponsored and hosted the launch of Healthcare Drinks' Boston Chapter in the firm's Boston office. Healthcare Drinks provides a platform for all sectors of management in the health care industry to meet, exchange ideas and socialize in a casual yet professional, educational and supportive atmosphere.



About Dr. Preston Estep
Dr. Estep performed his doctoral research at The Harvard Molecular Technology Group laboratory of genomics pioneer George Church. He is a Director of the Harvard Personal Genome Project. He is co-founder and Chief Scientific Officer of Veritas Genetics, a genetic testing company in the Boston area, which was recognized in 2016 and 2017 by MIT Technology Review as one of the world's 50 Smartest Companies.

Dr. Estep has co-founded and/or advised multiple startup companies and nonprofit organizations and is a frequent speaker to professional and public audiences. Dr. Estep is also Chairman and co-founder of the Mind First Foundation, which is dedicated to scientific research of the brain. He is the author of The Mindspan Diet, an examination of the longevity diets and genes throughout the world, which was published in 2016 by Ballantine Books/Random House.

About Greenberg Traurig's Life Sciences & Medical Technology Group
Greenberg Traurig's Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group's attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing. As part of the group, the Biotechnology and Pharmaceutical Industry Group focuses on advising clients in the biotechnology and pharmaceutical sectors.

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2017 Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.

Read the full story at http://www.prweb.com/releases/2018/02/prweb15192980.htm.


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • SourceLink Partners with MassMedia Health to Provide Medicare Age-In Data to Healthcare Groups
  • Driven by Boomers, Consumer-Driven Genetic Testing Forecasted to Reach $310 Million
  • Global Mobile Medical Apps Market to Reach $11.22 Billion by 2025, Reports BIS Research
  • U.S. Nebulizer Market Size Worth $435.5 Million By 2025 | CAGR 6.2%: Grand View Research, Inc.
  • Global Cables and Leads for Medical Equipment Industry

    Cancer
  • argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
  • CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
  • Varian Acquires Evinance Innovation, Inc.
  • QCCA Evolves to Become the First National Clinically Integrated Network in Oncology
  • COA: Analysis Shows Virginia Hospitals Benefit From Recent Changes In Medicare Payment
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines